• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:AU2008202998A1
    申请号:U2008202998
    申请日:2008-07-07
    公开日:2009-02-19
    发明作者:Joshua Stopek
    申请人:Tyco Healthcare Group LP；
    IPC主号:C08G63-64
    专利说明:
    S&F Ref: 865370
    AUSTRALIA
    PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT 00
    O
    oO
    (N
    Name and Address of Applicant: Actual Inventor(s): Address for Service: Invention Title: Tyco Healthcare Group LP, of 60 Middletown Avenue, North Haven, Connecticut, 06473, United States of America Joshua Stopek Spruson Ferguson St Martins Tower Level 31 Market Street Sydney NSW 2000 (CCN 3710000177) Carbonate copolymers The following statement is a full description of this invention, including the best method of performing it known to me/us: 5845c(1304877_1) CARBONATE COPOLYMERS TECHNICAL FIELD The present disclosure provides polymer compositions which are particularly 0oO useful in the manufacture of medical devices such as sutures, staples, clips, anastomosis rings, bone plates and screws, matrices for the sustained and/or controlled release of 00 oO pharmaceutically active ingredients, etc. In some embodiments, the polymer compositions may be utilized as coatings for medical devices.
    DESCRIPTION OF THE RELATED ART Polymers and copolymers of, and surgical devices made from, lactide and/or glycolide and/or related compounds are within the purview of those skilled in the art. In addition, other patents disclose surgical devices prepared from copolymers of lactide or glycolide and other monomers including caprolactone or trimethylene carbonate. For example, U.S. Patent Nos. 4,605,730 and 4,700,704 disclose copolymers of epsiloncaprolactone and glycolide useful in making surgical articles and particularly surgical sutures. In addition, U.S. Patent No. 4,624,256 relates to the utilization of high molecular weight caprolactone polymers as coatings for surgical sutures, while U.S. Patent No.
    4,429,080 discloses surgical articles manufactured from triblock copolymers prepared from copolymerizing glycolide with trimethylene carbonate.
    The properties of bioabsorbable polymers may differ considerably depending on the nature and amounts of the comonomers, if any, employed and/or the polymerization procedures used in preparing the polymers. The selection of such polymers for use in the 00 O formation of medical devices and coatings thereon may be influenced by the properties of the various polymers, including physical properties such as the tensile strength of the polymers and the length of time before loss of strength and/or degradation occurs, and the like.
    00 5 Although current medical devices and coatings thereon formed from bioabsorbable polymers may perform satisfactorily, there is room for improvement in connection with polymers having enhanced properties for the formation of medical 0devices and coatings on medical devices.
    1o SUMMARY According to a first aspect of the invention there is provided a method comprising: polymerizing at least one cyclic monomer in the presence of an aromatic cyclic carbonate to form a copolymer; and recovering the resulting copolymer.
    Copolymer compositions are provided which include a cyclic monomer and an aromatic cyclic carbonate. The copolymer may be produced, in embodiments, by a ringopening polymerization reaction initiated by the aromatic cyclic carbonate. In embodiments, methods for producing such copolymers include polymerizing at least one cyclic monomer in the presence of an aromatic cyclic carbonate to form a copolymer, and recovering the resulting copolymer.
    According to a second aspect of the invention there is provided a copolymer having the formula Ho-1W-1-{ A -J-H wherein W is a derivative obtained from a cyclic monomer selected from the group consisting of cyclic esters and cyclic carbonates, x is a number from about 1 to about 200, y is a number from about 1 to about 200, and A is an aromatic carbonate derivative obtained from an aromatic cyclic oligomeric carbonate of formula 00 0 C~1 Z-R-C 00 wherein R is an aromatic comprising benzene, Z comprises COO, and n is a 00 number from about 1 to about The resulting copolymer may be utilized in producing medical devices, drug delivery devices, and/or coatings for medical devices.
    DETAILED DESCRIPTION The compositions described herein are useful for the formation of medical devices, drug delivery devices, and/or coatings on medical devices. The compositions include copolymers formed by polymerizing a cyclic monomer in the presence of a cyclic carbonate possessing an aromatic group in its ring. Suitable cyclic monomers for use in forming the copolymers of the present disclosure possess desirable properties including reasonable reaction rates under suitable reaction conditions. The resulting copolymers are biocompatible, making them suitable for the fabrication of medical devices and coatings thereon, as well as drug delivery devices.
    Copolymers prepared in accordance with the present disclosure include at least one cyclic monomer as a first component of the copolymer. Suitable cyclic monomers include, for example, cyclic esters such as lactones, and cyclic carbonates. Suitable cyclic esters may include those having small rings, in embodiments 5-member rings, in 00 other embodiments 6-member rings, and in other embodiments 7-member rings. In some 0 C1 embodiments, suitable cyclic esters may possess a heteroatom, such as oxygen, adjacent to the a-carbon. Suitable cyclic esters include glycolide, L(-)-lactide, D(+)-lactide, meso- 0 lactide, p-dioxanone, 1,4-dioxan-2one, 1,5-dioxepan-2-one, epsilon-caprolactone, delta- 00 5 valerolactone, gamma-butyrolactone, beta-propiolactone, and combinations thereof.
    Suitable cyclic carbonates include, for example, ethylene carbonate, trimethylene N carbonate, dimethyl trimethylene carbonate, 3-ethyl-3-hydroxymethyl trimethylene 0O 0 carbonate, propylene carbonate, trimethylolpropane monocarbonate, 4,6 dimethyl-1,3propylene carbonate, 2,2-dimethyl trimethylene carbonate, 1,3-dioxepan-2-one, and combinations thereof.
    In embodiments, the copolymers of the present disclosure include a cyclic carbonate possessing an aromatic group in its ring. Such cyclic carbonates possessing aromatic groups include, for example, oligomeric cyclic carbonates possessing an aromatic group in the ring, sometimes referred to herein as "aromatic cyclic carbonates," "aromatic cyclic oligomeric carbonates," and derivatives thereof. Such aromatic cyclic oligomeric carbonates include, for example, those disclosed in Odian, "Principles of Polymerization" 3 rd ed., John Wiley Sons, Inc. pp. 569-573, the entire disclosure of which is incorporated by reference herein.
    In some embodiments, the aromatic cyclic oligomeric carbonate may be of the following formula: 00 0
    -Z-
    R
    -C
    (I)
    00 0 wherein R is an aromatic group such as benzene and the like; Z can be COO and 00 Sthe like; n may be a number from about 1 to about 30; and the remainder of the cyclic C 5 carbonate may possess from about 1 to about 30 carbon atoms, in embodiments from about 2 to about 15 carbon atoms, and may include, for example, cyclic carbonates derived from cyclic esters such as lactones, including butyrolactone, valerolactone, caprolactone, propiolactone, and combinations thereof, as well as other cyclic esters such as dioxanones, glycolide, lactide, bisphenol A, and combinations thereof.
    In embodiments, the aromatic cyclic carbonate may be of the following formula: O O 0 0
    F^U^C-
    0 i(ii)
    (II)
    In other embodiments, aromatic cyclic carbonates may include cyclic oligomeric carbonates derived from bisphenol A derivatives including bisphenol A, 2,2'-bis(4hydroxyphenyl)propane. Examples of such compounds include those of the following formula: 00
    Z
    00 00 -0 CH2(CH2, wherein m is a number from about 1 to about Copolymers of the present disclosure may be formed by combining the cyclic monomer and aromatic cyclic carbonate utilizing any method or process within the purview of those skilled in the art. In embodiments, copolymers of the present disclosure may be obtained by subjecting the cyclic monomers to a ring-opening polymerization reaction initiated by the aromatic cyclic carbonate. The result of such a polymerization reaction may include both an ester and/or carbonate derivatives from the cyclic monomer(s), and an aromatic carbonate derivative from the aromatic cyclic oligomeric carbonate. Thus, in some embodiments, the resulting copolymer may be of the following formula: HO-f WfJAf-H
    (IV)
    wherein W is a derivative obtained from the cyclic monomer, in embodiments an ester or carbonate; A is the aromatic carbonate derivative obtained from the aromatic cyclic 00 oligomeric carbonate; x is a number from about 1 to about 200, in embodiments from 0 Ci about 50 to about 150, and y is a number from about 1 to about 200, in embodiments from about 50 to about 150.
    SIn some embodiments, where the aromatic cyclic oligomeric carbonate has the 00 5 structure of formula II above, the resulting copolymer may have the following structure: 0 0 O
    (V)
    0O HO- W C wherein W, x, and y are as defined above.
    In other embodiments, where the aromatic cyclic oligomeric carbonate has the structure of formula III above, the resulting copolymer may have the following structure: HO+W -C(CH 3 2 -0-CO H
    (VI)
    wherein W, x and y are as defined above.
    The resulting copolymer may be of random, block, or alternate configuration. It should, of course, be understood that more than one cyclic monomer can be employed to form a copolymer of the present disclosure. Where the copolymer is a block copolymer, it may have any block configuration such as AB, ABA, ABAB, ABC, ABCBA, BABA, BACAB, ABCD, and the like.
    0 Methods for forming the copolymers of the present disclosure are within the purview of those skilled in the art, and may utilize standard reaction conditions that may be varied depending upon the cyclic monomers and aromatic cyclic oligomeric Scarbonates utilized to form the copolymers of the present disclosure. Cyclic monomers 00 5 and aromatic cyclic carbonates may be combined in any suitable amount, in any order, to form a copolymer of the present disclosure. In some embodiments, the cyclic monomers 00 and aromatic cyclic oligomeric carbonate(s) can be combined in the presence of a catalyst Ssuch as stannous octoate, sometimes under an inert atmosphere, such as nitrogen gas.
    In some cases it may be desirable to allow the polymerization to occur under a vacuum, at a pressure less than about 1 Torr. In some embodiments it may be desirable to heat the cyclic monomers and aromatic cyclic carbonates to a suitable temperature of from about 1700 C to about 185' C, in embodiments from about 175" C to about 180' C, in some cases to a temperature of about 178" C. The monomers may be allowed to polymerize for a suitable period of time from about 4 hours to about 6 hours, in embodiments from about 4.25 hours to about 4.75 hours.
    After this time, the molten copolymer may be obtained. While not necessary, in some embodiments the copolymer of the present disclosure may be subjected to a further heat treatment by heating to a temperature of from about 1000 C to about 1200 C, in embodiments from about 107 C to about 1130 C, for a period of time from about hours to about 35 hours, in embodiments from about 28 hours to about 32 hours. In some cases it may be desirable for this second heat treatment to occur under a vacuum, in embodiments at a pressure less than about 1 Torr.
    The derivative obtained from the cyclic monomer, in embodiments an ester or c carbonate, can constitute up to about 75% by total weight of the copolymer of the present disclosure, in embodiments from about 15% to about 75% by total weight of the copolymer of the present disclosure, in other embodiments from about 30% to about 00 5 by total weight of the copolymer of the present disclosure. Thus, the aromatic carbonate N derivative obtained from the aromatic cyclic oligomeric carbonate may constitute up to 00 about 85% by total weight of the copolymer of the present disclosure, in embodiments O from about 25% to about 85% by total weight of the copolymer of the present disclosure, in other embodiments from about 50% to about 70% by total weight of the copolymer of the present disclosure.
    In addition, the copolymers of the present disclosure may be combined with other biocompatible polymers, so long as they do not interfere undesirably with the biodegradable characteristics of the copolymer. Blends of the copolymers of the present disclosure with such other polymers may offer even greater flexibility in designing the precise release profile desired for targeted drug delivery or the precise rate of biodegradability desired for structural implants. Examples of such additional biocompatible polymers include other polycarbonates; polyesters; polyorthoesters; polyamides; polyurethanes; poly(iminocarbonates); polyanhydrides; and combinations thereof.
    In some embodiments, the copolymers of the present disclosure may be combined with a fatty acid component that contains a fatty acid or a fatty acid salt or a salt of a fatty acid ester. Suitable fatty acids may be saturated or unsaturated, and include higher fatty acids having more than about 12 carbon atoms. Suitable saturated fatty acids include, for 00 0 example, stearic acid, palmitic acid, myristic acid and lauric acid. Suitable unsaturated ,I fatty acids include oleic acid, linoleic acid, and linolenic acid. In addition, an ester of fatty acids, such as sorbitan tristearate or hydrogenated castor oil, may be used.
    Suitable fatty acid salts include the polyvalent metal ion salts of C 6 and higher 00 5 fatty acids, particularly those having from about 12 to 22 carbon atoms, and mixtures CN thereof. Fatty acid salts including the calcium, magnesium, barium, aluminum, and zinc 00 salts of stearic, palmitic and oleic acids may be useful in some embodiments of the Spresent disclosure. Particularly useful salts include commercial "food grade" calcium stearate which consists of a mixture of about one-third C 16 and two-thirds C 18 fatty acids, with small amounts of the C 1 4 and C 22 fatty acids.
    Suitable salts of fatty acid esters which may be combined with the copolymers of the present disclosure include calcium, magnesium, aluminum, barium, or zinc stearoyl lactylate; calcium, magnesium, aluminum, barium, or zinc palmityl lactylate; calcium, magnesium, aluminum, barium, or zinc olelyl lactylate; with calcium stearoyl-2-lactylate (such as the calcium stearoyl-2-lactylate commercially available under the tradename VERV from American Ingredients Co., Kansas City, Mo.) being particularly useful.
    Other fatty acid ester salts which may be utilized include those selected from the group consisting of lithium stearoyl lactylate, potassium stearoyl lactylate, rubidium stearoyl lactylate, cesium stearoyl lactylate, francium stearoyl lactylate, sodium palmityl lactylate, lithium palmityl lactylate, potassium palmityl lactylate, rubidium palmityl lactylate, cesium palmityl lactylate, francium palmityl lactylate, sodium olelyl lactylate, lithium olelyl lactylate, potassium olelyl lactylate, rubidium olelyl lactylate, cesium olelyl lactylate, and francium olelyl lactylate.
    00 0 In some embodiments it may be desirable to combine a copolymer of the present Sdisclosure with a wax. Suitable waxes which may be utilized include polyethylene wax, ethylene copolymer wax, halogenated hydrocarbon waxes, hydrogenated vegetable oil, beeswax, caranuba wax, paraffin, microcrystalline wax, candelillia, spermacetic wax, and 00 5 mixtures therebf.
    CN In other embodiments, omega-6 fatty acids, including arachidonic acid, may be 00 combined with the copolymers of the present disclosure.
    In yet additional embodiments, phospholipids may be combined with the copolymers of the present disclosure. Suitable phospholipids include, but are not limited to, phosphatidylcholine mono-acyl phosphatidylcholine (MAPC), diacyl phosphatidylcholine (DAPC), phosphatidylserine phosphatidylethanolamine (PE), phosphatidylinositol phosphatidylglycerol plasmalogen, sphingomyelin, ceramide, ciliatin, polymers having phospholipid groups, and derivatives thereof. In some embodiments copolymers having phosphorylcholine groups may be added to the compositions of the present disclosure, such as copolymers of 2-methacryloyloxyethyl phosphorylcholine with other monomers, including methacrylates such as butyl methacrylate, benzyl methacrylate, methacryloyloxyethyl phenylcarbamate, and phenyl methacryloyloxyethyl carbamate.
    In some embodiments, the copolymers of the present disclosure may also be combined with one or more bioactive agents and/or medicinal agents which may be retained in or released from the copolymers of the present disclosure. As used herein, "medicinal agent" is used in its broadest sense and includes any substance or mixture of 00 0 substances that have clinical use. Consequently, medicinal agents may or may not have pharmacological activity per se, a dye.
    The amount of medicinal agent present will depend upon the particular medicinal agent chosen, but in some embodiments the amount used will be from about 0.01 to about 00 5 10 by weight of the device or coating including the copolymer of the present C disclosure.
    00 Examples of classes of medicinal agents which may be combined or mixed with Sthe copolymers of the present disclosure include antimicrobials, analgesics, antipyretics, anesthetics, antiepileptics, antihistamines, anti-inflammatories, cardiovascular drugs, diagnostic agents, sympathomimetics, cholinomimetics, antimuscarinics, antispasmodics, hormones, growth factors, muscle relaxants, adrenergic neuron blockers, antineoplastics, immunosuppressants, gastrointestinal drugs, diuretics, steroids, polysaccharides, and enzymes. It is also intended that combinations of medicinal agents may be used.
    Suitable antimicrobial agents which may be combined with the copolymers of the present disclosure include triclosan, also known as 2,4,4'-trichloro-2'-hydroxydiphenyl ether, chlorhexidine and its salts, including chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride, and chlorhexidine sulfate, silver and its salts, including silver acetate, silver benzoate, silver carbonate, silver citrate, silver iodate, silver iodide, silver lactate, silver laurate, silver nitrate, silver oxide, silver palmitate, silver protein, and silver sulfadiazine, polymyxin, tetracycline, aminoglycosides, such as tobramycin and gentamicin, rifampicin, bacitracin, neomycin, chloramphenicol, miconazole, quinolones such as oxolinic acid, norfloxacin, nalidixic acid, pefloxacin, enoxacin and ciprofloxacin, penicillins such as oxacillin and pipracil, nonoxynol 9, 00 0 fusidic acid, cephalosporins, and combinations thereof. In addition, antimicrobial proteins and peptides such as bovine lactoferrin and lactoferricin B may be included as a medicinal agent in the blend or emulsion of the present disclosure.
    Other medicinal agents which may be combined with the copolymers of the 00 5 present disclosure include: local anesthetics; non-steroidal antifertility agents; C parasympathomimetic agents; psychotherapeutic agents; tranquilizers; decongestants; 00 sedative hypnotics; steroids; sulfonamides; sympathomimetic agents; vaccines; vitamins; Santimalarials; anti-migraine agents; anti-parkinson agents such as L-dopa; antispasmodics; anticholinergic agents oxybutynin); antitussives; bronchodilators; cardiovascular agents such as coronary vasodilators and nitroglycerin; alkaloids; analgesics; narcotics such as codeine, dihydrocodeinone, meperidine, morphine and the like; non-narcotics such as salicylates, aspirin, acetaminophen, d-propoxyphene and the like; opioid receptor antagonists, such as naltrexone and naloxone; anti-cancer agents; anti-convulsants; anti-emetics; antihistamines; anti-inflammatory agents such as hormonal agents, hydrocortisone, prednisolone, prednisone, non-hormonal agents, allopurinol, indomethacin, phenylbutazone and the like; prostaglandins and cytotoxic drugs; estrogens; antibacterials; antifungals; antivirals; anticoagulants; anticonvulsants; antidepressants; antihistamines; and immunological agents.
    Other examples of suitable medicinal agents which may be combined with copolymers of the present disclosure include viruses and cells, peptides luteinizinghormone-releasing-hormone analogues, such as goserelin and exendin) and proteins, analogs, muteins, and active fragments thereof, such as immunoglobulins, antibodies, cytokines lymphokines, monokines, chemokines), blood clotting factors, Shemopoietic factors, interleukins (IL-2, IL-3, IL-4, IL-6), interferons (1-IFN, (a-IFN and 0 I 7 -IFN), erythropoietin, nucleases, tumor necrosis factor, colony stimulating factors GCSF, GM-CSF, MCSF), insulin, enzymes superoxide dismutase, tissue
    O
    plasminogen activator), tumor suppressors, blood proteins, gonadotropins FSH, LH, 00 5 CG, etc.), hormones and hormone analogs growth hormone, adrenocorticotropic CI hormone and luteinizing hormone releasing hormone (LHRH)), vaccines tumoral, 00 bacterial and viral antigens); somatostatin; antigens; blood coagulation factors; growth factors nerve growth factor, insulin-like growth factor); protein inhibitors, protein antagonists, and protein agonists; nucleic acids, such as antisense molecules, DNA and RNA; oligonucleotides; and ribozymes.
    Imaging agents such as iodine or barium sulfate, or fluorine, can also be combined with the copolymers of the present disclosure to allow visualization of the surgical area through the use of imaging equipment, including X-ray, MRI, and CAT scan.
    Additionally, an enzyme may be added to the copolymers of the present disclosure to increase their rate of degradation. Suitable enzymes include, for example, peptide hydrolases such as elastase, cathepsin G, cathepsin E, cathepsin B, cathepsin H, cathepsin L, trypsin, pepsin, chymotrypsin, y-glutamyltransferase (7-GTP) and the like; sugar chain hydrolases such as phosphorylase, neuraminidase, dextranase, amylase, lysozyme, oligosaccharase and the like; oligonucleotide hydrolases such as alkaline phosphatase, endoribonuclease, endodeoxyribonuclease and the like. In some embodiments, where an enzyme is added, the enzyme may be included in a liposome or microsphere to control the rate of its release, thereby controlling the rate of degradation 00 0 of the biocompatible composition of the present disclosure. Methods for incorporating enzymes into liposomes and/or microspheres are known to those skilled in the art.
    Z In embodiments, surfactants such as phospholipid surfactants that provide antibacterial stabilizing properties and help disperse other materials in the copolymers of 00 5 the present disclosure, may also be added.
    As noted above, the copolymers of the present disclosure may be used to form a 0, medical device, a drug delivery device, or a coating for a substrate, such as a medical device.
    As a structural medical device, the copolymers of the present disclosure provide a physical form having specific chemical, physical, and mechanical properties sufficient for the desired application that eventually degrade in vivo into non-toxic residues.
    The copolymers described herein are non-toxic. As noted above, depending on their particular physical properties (to a large extent influenced by the nature of the cyclic monomers and aromatic cyclic carbonates from which they are prepared), the copolymers herein can be used in the fabrication in whole or in part of a variety of implantable medical devices and prostheses. Surgical and medical articles which may be prepared utilizing the copolymers of the present disclosure include, but are not necessarily limited to: burn dressings; hernia patches; medicated dressings; fascial substitutes; gauze, fabric, sheet, felt or sponge for liver hemostasis; arterial grafts or substitutes; bandages; orthopedic pins, clamps, screws, and plates; clips; staples; hooks, buttons, and snaps; bone substitutes mandible prosthesis); intrauterine devices spermicidal devices); draining or testing tubes or capillaries; surgical instruments; vascular implants or supports; vertebral discs; extracorporeal tubing for kidney and heart-lung machines; 00 0 artificial skin; catheters; scaffoldings for tissue engineering applications; sutures; suture N, coatings; and the like. Applied to a suture, a coating composition including the copolymers herein results in a suture having suitable lubricity, knot tiedown, and knot security characteristics.
    00 5 In embodiments, the copolymer, in combination with any optional medicinal N, agent, can also be melt processed using conventional extrusion or injection molding 00 techniques, or these products can be prepared by dissolving in an appropriate solvent, Sfollowed by formation of the device, and subsequent removal of the solvent by evaporation or extraction. For example, where the copolymers of the present disclosure are used to form a medical device, the devices may be made by injection molding at temperatures and pressures within the purview of those skilled in the art. Typically, the feed for the injection molding apparatus may be a melt blend of the copolymer of the present disclosure in pellet form. The copolymer should be quite dry when being injection molded in order to avoid hydrolytic degradation during processing. After molding, the resulting surgical device prepared from the copolymers of the present disclosure can be packaged and sterilized by conventional procedures. It may be desirable to anneal the devices to remove residual stresses and strains, to stabilize the shape of the device, and to reduce or eliminate defects in the piece. Annealing may include reheating the medical device to above its glass transition temperature where chain mobility is greatest, and then slowly and gradually cooling the device. Procedures, conditions and apparatus for annealing polymeric structures are within the purview of those skilled in the art.
    00 The copolymers of the present disclosure may also be formed into films and/or foams which, in turn, may be applied to wounds such as cuts, gashes, ulcers and burns to aid healing. Medicinal agents such as wound healing agents and antimicrobials may be incorporated to speed healing of damaged tissues. In this manner, various growth factors, 00 5 antibiotics and antifungals can be combined with the copolymers of the present i disclosure.
    00 In other embodiments, the copolymers of the present disclosure may be applied as a coating to a medical device. Suitable medical devices which may be coated with the polymer of the present disclosure include, any medical device described above. In embodiments, medical devices which may be coated with a copolymer of the present disclosure include surgical needles, staples, clips and other fasteners, drug delivery devices, stents, pins, screws, prosthetic devices, implantable devices, wound dressings, anastomosis rings, and fibrous surgical articles such as sutures, prosthetic ligaments, prosthetic tendons, woven mesh, gauze, dressings, growth matrices, and the like. Fibers coated with the present compositions can be knitted or woven with other fibers, either absorbable or nonabsorbable, to form meshes or fabrics.
    Copolymers of the present disclosure may be applied to a substrate as a coating, optionally combined with any of the additives described above, using any technique within the purview of those skilled in the art. Where the copolymers of the present disclosure are used as a coating for a medical device, the coating may be formed using any known technique such as, for example, extrusion, molding and/or solvent casting.
    The copolymer can be used alone, blended with other absorbable compositions, or blended with non-absorbable components.
    00 In one embodiment the copolymer of the present disclosure may be applied as a coating by dissolving it in a solvent which is a non-solvent for any polymeric device to which the coating is to be applied. The solution containing the copolymer of the present disclosure may then be applied to a medical device by dipping the medical device into the 00o 5 solution, by passing the medical device past a brush or other applicator, or by spraying C the solution onto the surface of the medical device. Suitable solvents for use in 00 dissolving the copolymer of the present disclosure include, but are not limited to, volatile Ssolvents such as methylene chloride, acetone, hexafluoro isopropanol (HFIP), tetrahydrofuran (THF), combinations thereof, and the like. The medical device wetted with the coating solution may then be subsequently passed through or held in a drying oven for a time and at a temperature sufficient to vaporize and drive off the solvent. If desired, the suture coating composition can optionally contain additional components, medicinal agents or similar additives described above including dyes, antibiotics, antiseptics, growth factors, anti-inflammatory agents, etc.
    Where the copolymer of the present disclosure is combined with an optional additive for use as a coating, if both the copolymer and additional material are soluble in the same solvent, the appropriate amounts of the copolymer and any additive can be dissolved in the solvent and applied to the medical device to be coated as a solution. For example, the copolymers of the present disclosure may be solubilized in a dilute solution of a volatile organic solvent, e.g. acetone, methanol, ethyl acetate or toluene, and then the article can be immersed in the solution to coat its surface. Upon evaporation of the solvent, optionally at elevated temperatures, a coating of the copolymer and any additive will remain on the medical device.
    0 Where applied in solution, the amount of solvent utilized can be from about c to about 99% by weight, in embodiments from about 90% to about 98% by weight of the solution utilized to apply the copolymer of the present disclosure, including any t"additional medicinal agents or adjuvants. In some embodiments the solvent may be 00 5 present at about 95% by weight of the solution utilized to apply the copolymer of the Ng present disclosure.
    00 While the copolymer herein can be applied to any type of medical device, it may
    O
    O be especially useful as a coating for a suture. The amount of copolymer applied to a suture will vary depending upon the structure of the suture, monofilament or multifilament, the size of the suture and its composition. For multifilament sutures, the number of filaments and the tightness of the braid or twist may also influence the amount of coating.
    The coating may be applied to both monofilament and multifilament braided sutures which may, in some embodiments, also be bioabsorbable. Suitable bioabsorbable monomers and polymers utilized for the sutures, including bioabsorbable braided sutures, include lactide, glycolide, trimethylene carbonate, e-caprolactone, caprolactam, polyesters, nylons, etc. The coating can be present in an amount from about 0.5 to about of the base suture substrate, in embodiments from about 1 to about 5% (w/w) of the base suture substrate. The thickness of the coating will depend on a number of factors, but typically can be from submicron thicknesses up to several millimeters in thickness.
    In other embodiments, where the copolymer of the present disclosure and an optional additive are not completely miscible with each other or any solvents utilized to 00 0 combine the two, emulsions may be formed and utilized by any means known to those skilled in the art to form medical devices including drug delivery devices or coatings for medical devices. For example, when a medicinal agent is combined with a copolymer of the present disclosure but it incompatible therewith, the medicinal agent may be placed in 00 5 solution, the copolymer of the present disclosure may be placed in a separate solution, N and the two combined to form an emulsion or suspension. Biocompatible dispersing 00 agents in the form of surfactants, emulsifiers, or stablilizers may be added to the blend to Sassist in dispersion of the medicinal agent throughout the copolymer of the present disclosure.
    Adjuvants may be added to stabilize or preserve the copolymers described above.
    Such adjuvants include nonionic surfactants which include alcohol ethoxylates, glycerol esters, polyoxyethylene esters, and glycol esters of fatty acids. Preferable nonionic surfactants are glycerol esters of stearic, oleic, and/or lauric acid as well as ethylene and/or diethylene glycol esters of fatty acids.
    The copolymers of the present disclosure, where utilized as a coating for a medical device, may improve surface properties of the device such as, for example, cell and protein adhesion, lubricity, drug delivery, protein or DNA delivery, etc. When used as a coating, the copolymers of the present disclosure may be especially useful in preventing bacterial adhesion/colonization, infection caused by or exacerbated by the device itself, and improving the handling properties of the device.
    In other embodiments, especially where the copolymer of the present disclosure is to be utilized to deliver a medicinal agent as a drug delivery device, it may be desirable to mix the medicinal agent with the copolymer of the present disclosure by processes such 00 0 as ball mill, disc mill, sand mill, attritor, rotor stator mixer, ultrasonication, etc. In other embodiments, the copolymer and any optional additive can be melt blended and used to form or coat a medical device. Other methods for making and using the copolymers of the present disclosure will be readily apparent to those skilled in the art.
    00 5 Where medicinal agents are combined with the copolymers of the present N, disclosure, the copolymers of the present disclosure may be utilized as a drug delivery 00 device to provide site-specific release of medicinal agents which may be immediate release, delayed release or sustained release. Immediate release systems provide a drug dose instantly. Delayed release systems provide repetitive intermittent dosings of drug.
    Sustained release systems achieve slow release of a drug over an extended period of time and should maintain a therapeutically effective concentration of drug at the target site.
    Medicinal agents that are mingled with the copolymers herein typically provide delayed or sustained release therapy by diffusion from a medical device formed from the copolymers herein and/or any coating formed from the copolymers as they degrade.
    It will be appreciated that various of the above-disclosed and other features and functions, or alternatives thereof, may be desirably combined into many other different systems or applications. Also that various presently unforeseen or unanticipated alternatives, modifications, variations or improvements therein may be subsequently made by those skilled in the art which are also intended to be encompassed by the following claims. Unless specifically recited in a claim, steps or components of claims should not be implied or imported from the specification or any other claims as to any particular order, number, position, size, shape, angle, color, or material.
    权利要求:
    Claims (16)
    [1] 2. The method of claim 1, wherein the at least one cyclic monomer is selected from the group consisting of cyclic esters and cyclic carbonates.
    [2] 3. The method of claim 1, wherein the at least one cyclic monomer comprises a cyclic ester selected from the group consisting of glycolide, L(-)-lactide, I0 D(+)-lactide, meso-lactide, p-dioxanone, 1,4-dioxan-2one, 1,5-dioxepan-2-one, epsilon- caprolactone, delta-valerolactone, gamma-butyrolactone, beta-propiolactone, and combinations thereof.
    [3] 4. The method of claim 1, wherein at least one cyclic monomer comprises a cyclic carbonate selected from the group consisting of ethylene carbonate, trimethylene 6 carbonate, dimethyl trimethylene carbonate, 3-ethyl-3-hydroxymethyl trimethylene carbonate, propylene carbonate, trimethylolpropane monocarbonate, 4,6 dimethyl-1,3- propylene carbonate, 2,2-dimethyl trimethylene carbonate, and 1,3-dioxepan-2-one, and combinations thereof. 00 O
    [4] 5. The method of claim 1, wherein the aromatic cyclic carbonate is of the formula 0 Z-R-C- n (I) wherein R is an aromatic comprising benzene, Z comprises COO, and n is a number from about 1 to about
    [5] 6. The method of claim 1, wherein the aromatic cyclic carbonate is of the formula O O (II)
    [6] 7. The method of claim 1, wherein the aromatic cyclic carbonate is of the formula: 00 00 CH 2 (CH 32 00 wherein m is a number from about I to about
    [7] 8. The method of claim i, wherein polymerizing the at least one cyclic monomer in the presence of the aromatic cyclic carbonate comprises heating the cyclic monomer and aromatic cyclic carbonate to a temperature of from about 170' C to about S 185' C, for a period of time from about 4 hours to about 6 hours.
    [8] 9. The method of claim 1, wherein polymerizing the at least one cyclic monomer in the presence of the aromatic cyclic carbonate comprises heating the cyclic monomer and aromatic cyclic carbonate to a temperature of from about 175° C to about 180° C, for a period of time from about 4.25 hours to about 4.75 hours. I 0 10. The method of claim 1, further comprising heating the copolymer to a temperature from about 100° C to about 120° C, for a period of time ranging from about hours to about 35 hours. 00
    [9] 11. The method of claim 1, further comprising heating the copolymer to a ;Z temperature from about 1070 C to about 1130 C, for a period of time ranging from about 28 hours to about 32 hours. 00
    [10] 12. A copolymer produced by the method of claim 1. 00 o 0S 13. A copolymer produced by the method of claim 1 having the formula HO-1-W fA -H (IV) wherein W is a derivative obtained from the cyclic monomer selected from the group consisting of esters and carbonates, A is an aromatic carbonate derivative obtained from the aromatic cyclic oligomeric carbonate, x is a number from about 1 to about 200, and y is a number from about 1 to about 200. t0 14. The copolymer of claim 13, wherein W comprises from about 15% to about 75% by total weight of the copolymer, and A comprises from about 20% to about by total weight of the copolymer. A copolymer produced by the method of claim 1 having the formula O O HO-WC-- (IV) 00 O wherein W is a derivative obtained from the cyclic monomer selected from the group consisting of esters and carbonates, x is a number from about 1 to about 200, and y is a number from about 1 to about 200.
    [11] 16. A copolymer produced by the method of claim 1 having the formula HO+ W C(CH 3 2 H (VI) wherein W is a derivative obtained from the cyclic monomer selected from the group consisting of esters and carbonates, x is a number from about 50 to about 150, and y is a number from about 50 to about 150.
    [12] 17. A medical device comprising the copolymer produced by the method of claim 1.
    [13] 18. of claim 1. A drug delivery device comprising the copolymer produced by the method
    [14] 19. A coating for a medical device comprising the copolymer produced by the method of claim 1. 00 A copolymer having the formula HO- Wf A H (IV) 00 wherein W is a derivative obtained from a cyclic monomer selected from the Sgroup consisting of cyclic esters and cyclic carbonates, x is a number from about I to C about 200, y is a number from about 1 to about 200, and A is an aromatic carbonate 00 O 5 derivative obtained from an aromatic cyclic oligomeric carbonate of formula 0 -Z-R- C (I) wherein R is an aromatic comprising benzene, Z comprises COO, and n is a number from about 1 to about
    [15] 21. The copolymer of claim 20, wherein W is a derivative obtained from a cyclic monomer selected from the group consisting ofglycolide, L(-)-lactide, D0 lactide, meso-lactide, p-dioxanone, 1,4-dioxan-2one, 1,5-dioxepan-2-one, epsilon- caprolactone, delta-valerolactone, gamma-butyrolactone, beta-propiolactone, ethylene carbonate, trimethylene carbonate, dimethyl trimethylene carbonate, 3-ethyl-3- hydroxymethyl trimethylene carbonate, propylene carbonate, trimethylolpropane 00 O monocarbonate, 4,6 dimethyl-1,3-propylene carbonate, 2,2-dimethyl trimethylene carbonate, and 1,3-dioxepan-2-one, and combinations thereof, and A is an aromatic carbonate derivative obtained from an aromatic cyclic carbonate selected from the group 0 consisting of formula 00 0 0 oO II II C -0 00 (II) and CH 2 (CH 3 2 m (III) f wherein m is a number from about 1 to about 00
    [16] 22. The copolymer of claim 20, wherein W comprises from about 15% to about 75% by total weight of the copolymer, and A comprises from about 20% to about t13 75% by total weight of the copolymer. Dated 4 August, 2008 Tyco Healthcare Group LP 00 Patent Attorneys for the Applicant/Nominated Person SSPRUSON FERGUSON 00 AH21(1334125 1):RTK
    类似技术:
    公开号 | 公开日 | 专利标题
    AU2005234622B2|2011-07-28|Novel biomaterial drug delivery and surface modification compositions
    AU2007221052B2|2013-05-16|Antimicrobial releasing polymers
    EP2181722B1|2015-01-14|Delayed gelation compositions and methods of use
    US6534560B2|2003-03-18|Bioresorbable hydrogel compositions for implantable prostheses
    US8263105B2|2012-09-11|Biomaterial drug delivery and surface modification compositions
    EP0693294A2|1996-01-24|Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
    AU2008202998B2|2014-01-23|Carbonate copolymers
    JP2012188664A|2012-10-04|Application of supercritical fluid technology for manufacturing soft tissue repair medical article
    JP2008272467A|2008-11-13|Coated filament
    JP2011019902A|2011-02-03|Method for coating medical device
    CN102258813A|2011-11-30|Medical anti-adhesion material and preparation method thereof
    US20120107366A1|2012-05-03|Block Copolymer Systems and Their Use in Medical Devices
    Shalaby et al.2003|Polyethylene Glycol-Based Copolyesters
    AU2011221369A1|2012-05-17|Block copolymer systems and their use in medical devices
    同族专利:
    公开号 | 公开日
    US20090036645A1|2009-02-05|
    AU2008202998B2|2014-01-23|
    EP2028210B1|2016-08-31|
    US7666973B2|2010-02-23|
    EP2028210A1|2009-02-25|
    JP2009030051A|2009-02-12|
    CA2635243A1|2009-01-30|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US32666A||1861-06-25||Improvement in plows |
    US33106A||1861-08-20||Basket |
    US157193A||1874-11-24||Improvement in car-couplings |
    US193884A||1877-08-07||Improvement in spinning mules and jacks |
    US3221025A|1961-12-21|1965-11-30|Gen Electric|Aromatic carbonates|
    US3301824A|1963-09-26|1967-01-31|Union Carbide Corp|Polymers of cyclic carbonates|
    US4195167A|1976-05-28|1980-03-25|Union Carbide Corporation|Gradient polymers of two or more cyclic, organic, ring-opening, addition polymerizable monomers and methods for making same|
    US4429080A|1982-07-01|1984-01-31|American Cyanamid Company|Synthetic copolymer surgical articles and method of manufacturing the same|
    US4700704A|1982-10-01|1987-10-20|Ethicon, Inc.|Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same|
    US4605730A|1982-10-01|1986-08-12|Ethicon, Inc.|Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same|
    US4605731A|1985-04-16|1986-08-12|General Electric Company|Method for preparing linear polycarbonate from cyclic oligomer with aryl carbanion generating catalyst|
    US4624256A|1985-09-11|1986-11-25|Pfizer Hospital Products Group, Inc.|Caprolactone polymers for suture coating|
    US4933430A|1987-03-05|1990-06-12|S. C. Johnson & Son, Inc.|Process for producing polymers useful in thermoset coatings and polymer so produced|
    US4791189A|1987-05-07|1988-12-13|The B. F. Goodrich Company|Terminally unsaturated macromolecular monomers of polylactones and copolymers thereof|
    DE3808837A1|1988-03-17|1989-09-28|Bayer Ag|MIXTURES OF AROMATIC POLYCARBONATES AND / OR AROMATIC POLYESTERS WITH SPECIAL COPOLYMERS|
    DE3831887A1|1988-09-20|1990-04-05|Bayer Ag|BLOCK COPOLYMERISATES BASED ON CYCLIC ALIPHATIC CARBONATES AND / OR ESTERS, ON THE ONE HAND, AND CYCLIC AROMATIC CARBONATES, OF THE OTHER PART|
    US4954593A|1989-08-18|1990-09-04|Gaf Chemical Corporation|Furanone/vinyl ether copolymers|
    US5013556A|1989-10-20|1991-05-07|Liposome Technology, Inc.|Liposomes with enhanced circulation time|
    US5252701A|1990-07-06|1993-10-12|American Cyanamid Company|Segmented absorbable copolymer|
    JP3414029B2|1994-03-04|2003-06-09|ダイセル化学工業株式会社|Monodisperse polymers and methods for their production|
    DE4435950A1|1994-10-07|1996-04-11|Hoechst Ag|Copolymers with cyclic or polycyclic monomers with a special isomer distribution and their use in coating compositions|
    US5889127A|1997-11-18|1999-03-30|Daicel Chemical Industries, Ltd.|Continuous process for the preparation of a polyester-based polymer|
    US6297349B1|1998-08-25|2001-10-02|Union Carbide Chemicals & Plastics Technology Corporation|Condensation copolymers having supressed crystallinity|
    WO1999019379A1|1997-10-15|1999-04-22|Daicel Chemical Industries, Ltd.|Processes for the preparation of monodisperse polymers, processes for the continuous polymerization of cyclic monomers, and polymers prepared thereby|
    EP1074566B1|1998-03-27|2013-07-17|Mitsubishi Rayon Co., Ltd.|Copolymer, process for producing the same, and resist composition|
    AUPP297898A0|1998-04-16|1998-05-07|Unisearch Limited|Production of furanones|
    US7151155B2|2001-04-17|2006-12-19|Union Carbide Chemicals & Plastics Technology Corporation|Copolymers of cyclic esters and cyclic formals|
    US6316581B1|2001-02-09|2001-11-13|Richard A. Gross|Bioresorbable copolymers|
    US6679822B2|2001-03-02|2004-01-20|Nof Corporation|Polyalkylene oxide-modified phospholipid and production method thereof|
    US6875832B2|2001-04-24|2005-04-05|Ppg Industries Ohio, Inc.|Synthesis of vinyl polymers by controlled radical polymerization|
    DE10138216A1|2001-08-03|2003-02-20|Bayer Ag|Production of aliphatic polycarbonate polymer e.g. poly polyol, involves ring-opening polymerization of cyclic carbonate in the presence of double metal cyanide catalyst|
    US6995228B2|2001-08-17|2006-02-07|Asahi Kasei Kabushiki Kaisha|Copolymer of conjugated cyclodiene|
    US6939554B2|2002-02-05|2005-09-06|Michigan Biotechnology Institute|Antimicrobial polymer|
    JP4480402B2|2002-03-29|2010-06-16|日油株式会社|Phospholipid derivative|
    US6831149B2|2002-06-28|2004-12-14|Ethicon, Inc.|Polymerization process using mono-and di-functional initiators to prepare fast crystallizing polylactone copolymers|
    US6794484B2|2002-06-28|2004-09-21|Ethicon, Inc.|Crystallizable polylactone copolymers prepared from mono- and di-functional polymerization initiators|
    CA2493771A1|2002-07-25|2004-02-05|Dsm Ip Assets B.V.|Process for the preparation of a block copolymer|
    US7148315B2|2002-10-23|2006-12-12|Ethicon, Inc.|Monomer addition techniques to control manufacturing of bioabsorbable copolymers|
    US6677419B1|2002-11-13|2004-01-13|International Business Machines Corporation|Preparation of copolymers|
    US6894133B2|2002-12-11|2005-05-17|3M Innovative Properties Company|Azlactone initiators for atom transfer radical polymerization|
    US20050208093A1|2004-03-22|2005-09-22|Thierry Glauser|Phosphoryl choline coating compositions|
    US20060079624A1|2004-10-08|2006-04-13|Hildeberto Nava|Crosslinkable polymer systems|
    CA2526541C|2004-12-01|2013-09-03|Tyco Healthcare Group Lp|Novel biomaterial drug delivery and surface modification compositions|
    US20090182337A1|2006-05-15|2009-07-16|Stopek Joshua B|Antimicrobial Coatings|
    EP2046932A2|2006-08-03|2009-04-15|Ciba Holding Inc.|Composition for improving wettability of surfaces|US20110151566A1|2009-12-23|2011-06-23|James Hedrick|Biodegradable polymers, complexes thereof for gene therapeutics and drug delivery, and methods related thereto|
    US8709466B2|2011-03-31|2014-04-29|International Business Machines Corporation|Cationic polymers for antimicrobial applications and delivery of bioactive materials|
    US8487017B2|2011-06-27|2013-07-16|Covidien Lp|Biodegradable materials for orthopedic devices based on polymer stereocomplexes|
    CN106255723B|2014-04-25|2019-03-22|宣伟投资管理有限公司|Polycyclic carbonate products and the polymer and composition formed by it|
    CN106459658B|2014-04-25|2019-04-23|宣伟投资管理有限公司|Polycyclic carbonate products and the polymer formed by it|
    法律状态:
    2014-05-22| FGA| Letters patent sealed or granted (standard patent)|
    2017-02-02| MK14| Patent ceased section 143(a) (annual fees not paid) or expired|
    优先权:
    申请号 | 申请日 | 专利标题
    US11/881,851||2007-07-30||
    US11/881,851|US7666973B2|2007-07-30|2007-07-30|Carbonate copolymers|
    [返回顶部]